TY - JOUR
T1 - Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder
AU - Tzang, R.-F.
AU - Wang, Y.-C.
AU - Yeh, C.-B.
AU - Hsu, C.-D.
AU - Liang, H.-Y.
AU - Yang, P.-C.
AU - Liu, H.-J.
AU - Huang, Yi-Shun
AU - Cheng, H.
AU - Hsu, Y.-C.
AU - Liu, S.-I.
AU - Pan, C.-H.
AU - Huang, Y.-F.
AU - Huang, C.-F.
AU - Wu, Y.-Y.
AU - Huang, Y.-H.
AU - Liu, H.-C.
AU - Chang, H.-L.
PY - 2012
Y1 - 2012
N2 - Aim: To determine the differences in the remission rate, recovery rate, functional improvement, and treatment adherence related to treatment with short-acting immediate-release methylphenidate (IR-MPH) and long-acting osmotic-release oral system-methylphenidate (OROS-MPH) in a naturalistic setting among Taiwanese children with attention-deficit-hyperactivity disorder (ADHD). Methods: A total of 757 children with ADHD, aged 6-18 years, was evaluated using the following in order determine functional improvement and treatment adherence: the Chinese version of the Swanson, Nolan, and Pelham, version IV scale (SNAP-IV-C), Clinical Global Impression-ADHD-Severity (CGI-S) to measure remission and recovery rates, the Chinese version of the Social Adjustment Inventory for Children and Adolescents (CSAICA), and caregiver's satisfaction rate, treatment adherence, and frequency of adverse effects. Results: According to the SNAP-IV-C scores, the remission rate was 30.72%, and the recovery rate was 16.38%. Compared to short-acting IR-MPH, OROS-MPH was associated with greater functional improvement and treatment adherence among children with ADHD. Conclusion: OROS-MPH treatment at the adequate dosage can achieve higher remission and recovery rates, produce greater functional improvement, and result in better treatment adherence than IR-MPH treatment. © 2012 Japanese Society of Psychiatry and Neurology.
AB - Aim: To determine the differences in the remission rate, recovery rate, functional improvement, and treatment adherence related to treatment with short-acting immediate-release methylphenidate (IR-MPH) and long-acting osmotic-release oral system-methylphenidate (OROS-MPH) in a naturalistic setting among Taiwanese children with attention-deficit-hyperactivity disorder (ADHD). Methods: A total of 757 children with ADHD, aged 6-18 years, was evaluated using the following in order determine functional improvement and treatment adherence: the Chinese version of the Swanson, Nolan, and Pelham, version IV scale (SNAP-IV-C), Clinical Global Impression-ADHD-Severity (CGI-S) to measure remission and recovery rates, the Chinese version of the Social Adjustment Inventory for Children and Adolescents (CSAICA), and caregiver's satisfaction rate, treatment adherence, and frequency of adverse effects. Results: According to the SNAP-IV-C scores, the remission rate was 30.72%, and the recovery rate was 16.38%. Compared to short-acting IR-MPH, OROS-MPH was associated with greater functional improvement and treatment adherence among children with ADHD. Conclusion: OROS-MPH treatment at the adequate dosage can achieve higher remission and recovery rates, produce greater functional improvement, and result in better treatment adherence than IR-MPH treatment. © 2012 Japanese Society of Psychiatry and Neurology.
KW - OROS-MPH
KW - attention-deficit-hyperactivity disorder
KW - functionality
KW - recovery rate
KW - remission rate
U2 - 10.1111/j.1440-1819.2011.02289.x
DO - 10.1111/j.1440-1819.2011.02289.x
M3 - Journal Article
SN - 1323-1316
VL - 66
SP - 53
EP - 63
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
IS - 1
ER -